Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

Provitro

Status: Completed

Conditions: Mutations in Exons 18 to 21

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01215474

AZ-NSCLC 18+

Details and patient eligibility

About

While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).

Enrollment: 500 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• NSCLC Stadium III-IV

Exclusion criteria

• no NSCLC or different stadium

Trial design

500 participants in 1 patient group

NSCLC Stadium III-IV